Verici Dx PLC (VRCI), the UK-listed transplant diagnostics company, has disclosed that Cantor Fitzgerald Europe reduced its holding in the firm from 6.21% to 3.62% of voting rights, crossing a regulatory threshold on 28 October 2026. The TR-1 notification, submitted to the issuer on 29 October 2026, reveals that Cantor Fitzgerald Europe now holds 240,925,000 direct voting rights in Verici Dx. The reduction represents a significant decrease in one of the company's notable institutional positions, a development investors in the small-cap diagnostics firm are likely to monitor closely.

Key Points

  • Verici Dx PLC (VRCI) — UK-listed transplant diagnostics company (ISIN: GB00BM8HZD43)
  • Cantor Fitzgerald Europe's voting rights fell from 6.21% to 3.62% following an acquisition or disposal of financial instruments
  • The threshold was crossed on 28 October 2026; the issuer was notified on 29 October 2026; 240,925,000 direct voting rights now held
  • Investors may watch whether further threshold crossings occur or whether other institutional holders adjust their positions

Cantor Fitzgerald Europe's Voting Rights in Verici Dx Drop Below 4% Threshold

According to the TR-1 standard notification filed with Verici Dx PLC, Cantor Fitzgerald Europe's total voting rights position fell to 3.62% from a previous notified level of 6.21%. All 240,925,000 voting rights are held directly, with no indirect holdings and no financial instruments such as options or contracts for difference contributing to the total. The notification confirms the reduction arose from an acquisition or disposal of financial instruments, though the specific nature of the transaction and the value involved were not disclosed in the announcement. Cantor Fitzgerald Europe is registered in Great Britain.

Verici Dx's Regulatory Disclosure Obligations Under DTR5

The notification was made under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules, specifically DTR5, which requires major shareholders to notify issuers when their holding crosses certain percentage thresholds. In this instance, the crossing of the threshold on 28 October 2026 triggered a mandatory disclosure, completed in London on 29 October 2026. The announcement states that Cantor Fitzgerald Europe is not controlled by any natural person or legal entity and does not itself control any other undertaking holding an interest in Verici Dx, providing clarity on the shareholder's independence for regulatory purposes.

What the Reduced Stake Means for Verici Dx's Shareholder Register

Verici Dx is focused on developing proprietary diagnostic tests aimed at improving outcomes in kidney transplantation, operating within the precision diagnostics sector. A reduction in a substantial institutional holding of this scale — from above 6% to below 4% — alters the composition of the company's shareholder register and may influence future voting dynamics at general meetings. The company did not disclose any commentary on the transaction in the announcement. Investors may be watching whether the remaining 3.62% stake held by Cantor Fitzgerald Europe is maintained or reduced further in subsequent reporting periods.